|
Drug Eruptions
|
0.300 |
Biomarker
|
group |
CTD_human |
[Screening and identification of differential serum proteins related to dermatitis medicamentosa-like of trichloroethylene].
|
21055120 |
2010 |
|
Morbilliform Drug Reaction
|
0.300 |
Biomarker
|
disease |
CTD_human |
[Screening and identification of differential serum proteins related to dermatitis medicamentosa-like of trichloroethylene].
|
21055120 |
2010 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Within the apolipoprotein A-I-C-III-A-IV gene cluster, the Ssti polymorphism in the 3' untranslated region of the apolipoprotein C-III gene is the variant site most consistently and strongly associated with raised plasma triglyceride levels and coronary artery disease.
|
9211063 |
1997 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Within the apolipoprotein A-I-C-III-A-IV gene cluster, the Ssti polymorphism in the 3' untranslated region of the apolipoprotein C-III gene is the variant site most consistently and strongly associated with raised plasma triglyceride levels and coronary artery disease.
|
9211063 |
1997 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Within the apolipoprotein A-I-C-III-A-IV gene cluster, the Ssti polymorphism in the 3' untranslated region of the apolipoprotein C-III gene is the variant site most consistently and strongly associated with raised plasma triglyceride levels and coronary artery disease.
|
9211063 |
1997 |
|
Triglycerides measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Whole genome sequencing and imputation in isolated populations identify genetic associations with medically-relevant complex traits.
|
28548082 |
2017 |
|
High density lipoprotein measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Whole genome sequencing and imputation in isolated populations identify genetic associations with medically-relevant complex traits.
|
28548082 |
2017 |
|
Hypertensive disease
|
0.060 |
GeneticVariation
|
group |
BEFREE |
While there is no evidence for a significant association of several common lipoprotein-related genetic variants with carotid IMT, our results are consistent with the previously reported role of CETP and LPL genetic variants in cardiovascular risk and the possible modulation of the association between hypertension and carotid IMT by APOCIII Sst-1 variant.
|
16430904 |
2006 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
While loss of insulin response is associated with unrestrained apoC-III production and impaired triglyceride metabolism, these data suggest that Foxo1 provides a molecular link between insulin deficiency or resistance and aberrant apoC-III production in the pathogenesis of diabetic hypertriglyceridemia.
|
15546000 |
2004 |
|
Hyperlipidemia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
When stratifying by hyperlipidemia, CAD patients with hyperlipidemia had a significantly higher frequency of APOC3 3238 GG genotype (OR =1.73, 95% CI =1.13, 2.64; P = 0.01) than without hyperlipidemia.
|
25380998 |
2014 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
When put in the context of studies demonstrating significant protection from cardiovascular events in individuals with loss of function variants in the APOC3 gene, our results provide strong evidence that therapies which increase the efficiency of conversion of VLDL to LDL, thereby reducing remnant concentrations, should reduce the risk of cardiovascular disease.
|
30580564 |
2019 |
|
Congenital Disorders of Glycosylation
|
0.040 |
Biomarker
|
group |
BEFREE |
When compared with age-matched controls, COG5-CDG showed a significant increase of apoC-III<sub>0a</sub> (aglycosylated glycoform), whereas apoC-III<sub>1</sub> (mono-sialylated glycoform) decreased significantly.
|
28444691 |
2017 |
|
Hypothyroidism
|
0.200 |
Biomarker
|
disease |
RGD |
We therefore measured the transcriptional activity of the apoA-IV and apoC-III genes and the abundance of their nuclear RNA and total cellular mRNA in livers of control rats and rats made hyper- and hypothyroid.
|
8429259 |
1993 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.270 |
GeneticVariation
|
disease |
BEFREE |
We therefore hypothesize haplotypes within the apoCIII gene are associated with type 1 diabetes.
|
16505251 |
2006 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We studied the association of HDL cholesterol (HDL-C), apoA1, apoCIII, apoD, and apoE as well as the ratios of apolipoproteins with apoA1 with the risk of T2D.
|
28031419 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We studied the association between the genes patatin-like phospholipase domain-containing protein 3 (PNPLA3) and apolipoprotein C3 (APOC3) and metabolic and histological parameters of NAFLD in obese patients.
|
23512881 |
2013 |
|
Hypertriglyceridemia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
We studied apoCIII gene polymorphisms, apolipoprotein E genotypes and lipoprotein-lipase gene mutations in 176 patients with Type II (non-insulin-dependent) diabetes mellitus, either normolipaemic (group N, n = 116), mildly hypertriglyceridaemic (group T, n = 28) or with a history of severe hypertriglyceridaemia (triglyceride > 15 g/l) (group H, n = 32).
|
11126401 |
2000 |
|
Dyslipidemias
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We sought to identify single nucleotide polymorphisms (SNPs) associated with apoC-III level response to combination therapy with statins and fenofibric acid (FA) in individuals with mixed dyslipidemia.
|
22236405 |
2012 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We showed that ApoC3-transgenic mice, as opposed to age/sex-matched wild-type littermates, develop hypertriglyceridemia with concomitant elevations in plasma cholesterol and non-esterified fatty acid levels.
|
27226540 |
2016 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We show that expression of a mouse apoC-III transgene can also cause hypertriglyceridemia with a similar accumulation of a VLDL-like particle with increased apoC-III and decreased apoE.
|
8864964 |
1996 |
|
Cholesteryl Ester Transfer Protein Deficiency
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
We set out to investigate the prevalence and clinical consequences of APOC3 mutations in individuals with hyperalphalipoproteinemia.
|
23701270 |
2014 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We sequenced APOC3 3'UTR in 100 type 2 diabetic (TD2) patients with severe HTG (TG > 15 mmol/L) (HTG group) compared to 100 normotriglyceridemic patients (NTG group).
|
27794214 |
2016 |
|
Thanatophoric dysplasia, type 2
|
0.010 |
Biomarker
|
disease |
BEFREE |
We sequenced APOC3 3'UTR in 100 type 2 diabetic (TD2) patients with severe HTG (TG > 15 mmol/L) (HTG group) compared to 100 normotriglyceridemic patients (NTG group).
|
27794214 |
2016 |
|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We measured apoC3 concentration change in patients with CHD before and after long-term aerobic exercise.
|
30511426 |
2019 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated how the presence of apoC-III affects the association between HDL and early stages of atherosclerosis measured as carotid intima-media thickness (cIMT).
|
29351856 |
2018 |